Why Agenus Inc.’s (AGEN) Stock Is Down 8.02%
As of Tuesday, October 06, Agenus Inc.’s AGEN share price has dipped by 8.02%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Commentary & Analysis
Why Agenus Inc.’s (AGEN) Stock Is Down 5.63%
As of Thursday, October 01, Agenus Inc.’s AGEN share price has dipped by 5.63%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Agenus Inc.’s (AGEN) Stock Is Up 6.03%
As of Monday, September 28, Agenus Inc.’s AGEN share price has surged by 6.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Agenus Inc.’s (AGEN) Stock Is Up 5.61%
As of Monday, September 21, Agenus Inc.’s AGEN share price has surged by 5.61%, which has investors questioning if this is right time to sell.Jenna Brashear
3 Undervalued Biotechnology Stocks for Wednesday, September 16
Discover the top 3 undervalued Biotechnology stocks for Wednesday, September 16 based on AAII’s Stock Grades.Tudor Pop
Financial Summary
| Share Statistics | AGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $345.3 | $242.6 | 33% |
|
| Shares Out (Mil) | 41.3 | 54.0 | 43% |
|
| Institutional Ownership | 96.4% | 93.1% | 70% |
|
| Float (Mil) | 40.2 | 41.4 | 42% |
|
| Beta | 1.40 | 0.95 | 79% |
|
| Avg Daily Volume (000s) | 1,423 | 633 | 76% |
|
| Price Change (52-week) |
83.9% | 50.0% | 92% |
|
| Growth | AGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.3% | 12.5% | 38% |
|
| Net Income (5yr) | 14.9% | (10.1%) | 63% |
|
| EPS (5yr) | 83.0% | 15.8% | 98 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.9%) | (15.7%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | na | 1 | |
| Current EPS | $0.040 | $0.247 | ($0.110) | |
| Month Ago EPS | $0.040 | $0.870 | ($0.060) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.900 | $0.500 | na | |
| Year/Year Chg | (366.7%) | (8,333%) | 8,233% | |
| Financials | AGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $133 | $37 | 29% |
|
| Net Income (TTM) (Mil) | $92 | ($44) | 60% |
|
| EPS (TTM) | $2.521 | ($1.600) | 75% |
|
| Operating Cash Flow (TTM) (Mil) | ($99) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $2 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $325 | $177 | 30% |
|
| Valuation | AGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.33 | na |
|
| P/E | 3.1 | 19.6 | 3% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.0 | 1.0 | 1% |
|
| Ratios | AGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 113.6% | 67.3% | 100% |
|
| Net Margin | 69.3% | (74.8%) | 98% |
|
| ROA | 51.4% | (47.6%) | 99% |
|
| ROE | (33.2%) | (54.9%) | 19% |
|
| Liabilities to Assets | 219.2% | 29.3% | 99% |
|
| F-Score | 5 | 3 | 50% |
|
Agenus Inc. did not pass any screens on 10/9/2026.
